BioCentury | Sep 12, 2019
Distillery Therapeutics

A mAb blocking IL-1 co-receptor for inflammatory, autoimmune diseases

DISEASE CATEGORY: Inflammation; autoimmune disease INDICATION: Inflammation; allergy; psoriasis A mAb against the IL-1 family co-receptor IL1RAP could treat peritonitis, allergic airway inflammation and psoriasis. The anti-IL1RAP mAb, which has an Fc domain mutated to...
BioCentury | Dec 15, 2017
Clinical News

Cantargia reports Phase I/IIa data for cancer candidate CAN04

...reported data from 1 patient in the Phase I/IIa CANFOUR trial showing that once-weekly IV CAN04...
...adverse events. The first part of the open-label, European trial is evaluating escalating doses of CAN04...
...pancreatic cancer, colorectal cancer or triple-negative breast cancer (TNBC), and the second part will evaluate CAN04...
BioCentury | Nov 19, 2015
Product R&D

A solid move

...of its lead program from cancers of the blood to solid tumors. After finding its anti-IL-1RAP mAb...
...planned indication of chronic myelogenous leukemia (CML). The Lund University spinout built its lead compound, CAN04...
...need is lower, and the indication didn't fully capitalize on the immune defense properties of CAN04...
BioCentury | Feb 27, 2012
Clinical News

Cantargia preclinical data

...Cantargia said its anti-IL-1RAP mAb significantly inhibited tumor growth in an animal model of malignant melanoma. Details...
...plans to identify a lead compound by year end. Cantargia AB , Lund, Sweden Product: Anti-IL-1RAP mAb...
BioCentury | Jan 30, 2012
Emerging Company Profile

Cantargia: Stemming CML

...much lower concentration, so the company hopes there will not be enough to sequester an anti-IL-1RAP mAb...
Items per page:
1 - 5 of 5